Cymabay Therapeutics Stock News

CymaBay Therapeutics has made continuous progress advancing its lead asset, seladelpar.

CymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Equities research analysts predict that CymaBay Therapeutics, Inc. (NASDAQ:CBAY) will announce ($0.34) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for CymaBay Therapeutics earnings. The lowest EPS estimate is ($0.38) and the highest is ($0.24). CymaBay Therapeutics reported earnings of ($0.23) per share in the same []

Different market evaluation and appropriate data techniques are often used to compile and evaluate the data which is offered in this Hypercholesterolemia Treatment market report. In addition, we have an in-house information prediction model that forecasts product demand until 2027.

Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) have received a consensus rating of Buy from the eight brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The []

Equities research analysts expect that CymaBay Therapeutics, Inc. (NASDAQ:CBAY) will report earnings per share of ($0.34) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for CymaBay Therapeutics earnings, with estimates ranging from ($0.38) to ($0.24). CymaBay Therapeutics posted earnings per share of ($0.23) during the same quarter last year, which []

CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded at $3.46 at close of the session on Monday, 11/29/21, made a downward move of -8.22% on its previous days price. Looking at the stock we see that its previous close was $3.77 and the beta (5Y monthly) reads 1.19 with the days price range being $3.32 $3.805. In CymaBay Therapeutics Inc. (NASDAQ: CBAY) Has Been Trading Down. What Are The Prospects For The Future? Read More »

State Street Corp grew its stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) by 5.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,357,224 shares of the biopharmaceutical companys stock after acquiring an additional 66,378 shares during the period. State Street Corp owned about 1.97% of []

LCM Capital Management Inc acquired a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the biopharmaceutical companys stock, valued at approximately $37,000. Several other large []

Cubist Systematic Strategies LLC reduced its holdings in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) by 57.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,700 shares of the biopharmaceutical companys stock after selling 87,740 shares during the quarter. Cubist Systematic Strategies LLC []

During the last session, CymaBay Therapeutics Inc. (NASDAQ:CBAY)s traded shares were 0.39 million, with the beta value of the company hitting 1.05. At the end of the trading day, the stocks price was $3.80, reflecting an intraday gain of 1.06% or $0.04. The 52-week high for the CBAY share is $7.77, that puts it down During The Past Six Months, CymaBay Therapeutics Inc. (NASDAQ: CBAY) Shares Took An -9.74% Jump. Here Is What We Should Expect Read More »

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) B. Riley boosted their FY2021 earnings estimates for shares of CymaBay Therapeutics in a research note issued to investors on Tuesday, November 16th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($1.29) per share for the year, up from their prior forecast of []

Lake Street Financial LLC acquired a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,900 shares of the biopharmaceutical companys stock, valued at approximately $47,000. Several other large investors have also []

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia Gene Therapy Candidate Roche H